| Primary |
| Prophylaxis Against Graft Versus Host Disease |
25.1% |
| Renal Transplant |
14.1% |
| Immunosuppression |
10.4% |
| Immunosuppressant Drug Therapy |
5.4% |
| Nephrotic Syndrome |
5.4% |
| Graft Versus Host Disease |
5.1% |
| Surgical Preconditioning |
5.1% |
| Prophylaxis |
3.8% |
| Stem Cell Transplant |
3.5% |
| Histiocytosis Haematophagic |
2.7% |
| Prophylaxis Against Transplant Rejection |
2.4% |
| Interstitial Lung Disease |
2.3% |
| Bone Marrow Transplant |
2.0% |
| Aplastic Anaemia |
2.0% |
| Heart Transplant |
1.9% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Bone Marrow Conditioning Regimen |
1.7% |
| Infection Prophylaxis |
1.7% |
| Liver Transplant |
1.7% |
| Psoriasis |
1.7% |
|
| Toxicity To Various Agents |
12.3% |
| Thrombotic Microangiopathy |
8.5% |
| Renal Impairment |
8.0% |
| Sepsis |
7.1% |
| Malignant Neoplasm Progression |
6.1% |
| Graft Versus Host Disease |
5.7% |
| Pyrexia |
5.7% |
| Respiratory Failure |
5.7% |
| Interstitial Lung Disease |
5.2% |
| Vomiting |
4.7% |
| Infection |
3.8% |
| Renal Failure Acute |
3.3% |
| Transplant Rejection |
3.3% |
| Venoocclusive Disease |
3.3% |
| Zygomycosis |
3.3% |
| Drug Ineffective |
2.8% |
| Multi-organ Failure |
2.8% |
| Natural Killer Cell Count Increased |
2.8% |
| Renal Failure |
2.8% |
| Rhabdomyolysis |
2.8% |
|
| Secondary |
| Prophylaxis Against Renal Transplant Rejection |
14.9% |
| Product Used For Unknown Indication |
14.1% |
| Renal Transplant |
11.0% |
| Prophylaxis Against Transplant Rejection |
9.2% |
| Heart Transplant |
8.8% |
| Prophylaxis Against Graft Versus Host Disease |
6.9% |
| Immunosuppression |
5.9% |
| Prophylaxis |
5.6% |
| Hypertension |
3.7% |
| Infection Prophylaxis |
3.0% |
| Bone Marrow Conditioning Regimen |
2.3% |
| Surgical Preconditioning |
2.1% |
| Acute Myeloid Leukaemia |
1.9% |
| Immunosuppressant Drug Therapy |
1.9% |
| Aplastic Anaemia |
1.7% |
| Rheumatoid Arthritis |
1.7% |
| Stem Cell Transplant |
1.5% |
| Histiocytosis Haematophagic |
1.4% |
| Osteoporosis |
1.3% |
| Pustular Psoriasis |
1.2% |
|
| Metastases To Liver |
15.0% |
| Ureteric Stenosis |
11.2% |
| Osteonecrosis |
9.7% |
| Vomiting |
6.4% |
| Sepsis |
5.6% |
| Urinary Tract Infection |
4.5% |
| Pancytopenia |
4.1% |
| Renal Failure Acute |
4.1% |
| Tendon Rupture |
4.1% |
| Malignant Neoplasm Progression |
3.7% |
| Renal Impairment |
3.7% |
| Blood Creatinine Increased |
3.4% |
| Pyrexia |
3.4% |
| Urinary Tract Infection Pseudomonal |
3.4% |
| Venoocclusive Disease |
3.4% |
| Venoocclusive Liver Disease |
3.4% |
| Transplant Failure |
3.0% |
| Death |
2.6% |
| Rhabdomyolysis |
2.6% |
| Thrombotic Microangiopathy |
2.6% |
|
| Concomitant |
| Prophylaxis |
22.1% |
| Aplastic Anaemia |
17.1% |
| Product Used For Unknown Indication |
11.6% |
| Infection Prophylaxis |
10.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.2% |
| Antiviral Prophylaxis |
3.5% |
| Hypertension |
3.5% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Constipation |
2.9% |
| Premedication |
2.8% |
| Bone Marrow Conditioning Regimen |
2.6% |
| Rheumatoid Arthritis |
2.5% |
| Acute Lymphocytic Leukaemia |
2.4% |
| Psoriasis |
2.2% |
| Anxiety Disorder |
2.1% |
| Insomnia |
1.8% |
| Antifungal Prophylaxis |
1.6% |
| Immunosuppression |
1.5% |
| Pain |
1.3% |
| Prophylaxis Against Transplant Rejection |
1.2% |
|
| White Blood Cell Count Decreased |
14.5% |
| Pneumonia |
9.6% |
| Rotavirus Infection |
7.2% |
| Pyrexia |
6.6% |
| Renal Impairment |
6.0% |
| Thrombotic Microangiopathy |
5.4% |
| Vomiting |
5.4% |
| Venoocclusive Liver Disease |
4.8% |
| Viral Haemorrhagic Cystitis |
4.2% |
| Colitis Ulcerative |
3.6% |
| Death |
3.6% |
| Nephrotic Syndrome |
3.6% |
| Off Label Use |
3.6% |
| Stomatitis |
3.6% |
| Visual Impairment |
3.6% |
| Febrile Neutropenia |
3.0% |
| Infection |
3.0% |
| Therapeutic Response Decreased |
3.0% |
| Venoocclusive Disease |
3.0% |
| Gastric Ulcer |
2.4% |
|
| Interacting |
| Product Used For Unknown Indication |
19.7% |
| Antibiotic Prophylaxis |
8.5% |
| Hiv Infection |
6.4% |
| Still's Disease Adult Onset |
6.4% |
| Immunosuppressant Drug Therapy |
5.9% |
| Coronary Artery Disease |
5.3% |
| Immunosuppression |
5.3% |
| Antiretroviral Therapy |
4.8% |
| Gout |
4.3% |
| Vulvovaginal Candidiasis |
3.7% |
| Bronchiolitis |
3.2% |
| Glomerulonephritis Minimal Lesion |
3.2% |
| Graft Versus Host Disease |
3.2% |
| Heart And Lung Transplant |
3.2% |
| Liver Transplant |
3.2% |
| Nephrotic Syndrome |
3.2% |
| Prophylaxis |
3.2% |
| Tuberculosis |
3.2% |
| Anticoagulant Therapy |
2.1% |
| Aspergillus Infection |
2.1% |
|
| Immunosuppressant Drug Level Increased |
16.3% |
| Haemorrhage |
9.3% |
| Therapeutic Response Decreased |
9.3% |
| Haemoglobin Decreased |
7.0% |
| Hepatotoxicity |
7.0% |
| International Normalised Ratio Increased |
7.0% |
| Immunosuppressant Drug Level Decreased |
4.7% |
| Renal Impairment |
4.7% |
| Rhabdomyolysis |
4.7% |
| Toxicity To Various Agents |
4.7% |
| Vision Blurred |
4.7% |
| Cytolytic Hepatitis |
2.3% |
| Drug Interaction |
2.3% |
| Drug Level Increased |
2.3% |
| Drug Therapeutic Incompatibility |
2.3% |
| Multi-organ Failure |
2.3% |
| Productive Cough |
2.3% |
| Renal Failure |
2.3% |
| Serum Ferritin Decreased |
2.3% |
| White Blood Cell Count Increased |
2.3% |
|
